Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-23

Clinical Trial Update: Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia [Phase 1, Phase 2]

View source ↗

Summary

This document notes the completion of a dose-escalation, Phase 1/2 trial of QLT0074 for benign prostatic hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QLT0074

Snippet

Sponsor: QLT Inc. | Conditions: Benign Prostatic Hyperplasia | Phase 1, Phase 2 | Status: COMPLETED